Mode
Text Size
Log in / Sign up

Low-dose N-acetylcysteine reduces acute exacerbation risk in patients with chronic obstructive pulmonary diseaseN-acetylcysteine may reduce flare ups for people with COPD

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider low-dose N-acetylcysteine (≤600 mg/day) to reduce acute exacerbation risk in patients with COPD.

This meta-analysis evaluated the impact of N-acetylcysteine (NAC) on patients with chronic obstructive pulmonary disease (COPD). The study analyzed data from 2,856 patients to determine the efficacy of NAC in reducing acute exacerbations and improving secondary outcomes such as pulmonary function and quality of life.

The primary finding indicates that NAC reduced the incidence of acute exacerbations compared to control groups (RR = 0.87; 95% CI [0.79-0.96], p=0.006). Specifically, low-dose NAC (≤600 mg/day) showed a significant reduction in risk (RR = 0.84; 95% CI [0.73-0.97], p=0.02), while high-dose NAC (>600 mg/day) did not reach statistical significance (RR = 0.88; 95% CI [0.73-1.06], p=0.19).

Secondary outcomes, including forced expiratory volume in one second (FEV1), forced vital capacity (FVC), St. George's Respiratory Questionnaire scores, and glutathione (GSH) levels, did not show significant improvement. The authors note that evidence does not indicate clear benefits for pulmonary ventilation, quality of life, or GSH levels. NAC was not associated with an increased risk of adverse events compared to the control group.

How this fits prior evidence

This meta-analysis addresses a gap in managing acute exacerbations in COPD. While prior coverage noted that biologic therapies targeting T2 inflammatory pathways reduce exacerbation rates in COPD patients, this finding suggests that low-dose N-acetylcysteine (≤600 mg/day) also provides a statistically significant reduction in exacerbation risk (RR = 0.84).

Living with chronic obstructive pulmonary disease (COPD) often means dealing with unpredictable flare-ups, known as acute exacerbations. These sudden worsening of symptoms can be frightening and difficult to manage. New data suggests that a specific type of supplement might help keep these episodes at bay.

A large review of clinical trials involving over 2,800 patients looked at the effects of N-acetylcysteine (NAC). The findings showed that NAC reduced the number of flare-ups compared to a control group. Interestingly, this benefit was most clear in patients taking a lower dose of less than or equal to 600 mg per day. In contrast, higher doses did not show a statistically significant benefit.

While the supplement helped reduce these sudden breathing issues, it did not significantly improve other measures like lung function (FEV1 and FVC) or quality of life scores. The treatment was also found to be safe, as it was not linked to an increased risk of side effects. Because results vary by dosage, patients should talk to their doctor about whether this specific treatment fits their personal health needs.

What this means for you:
Low-dose N-acetylcysteine may reduce the frequency of sudden flare-ups in people with COPD.

Common questions

Does N-acetylcysteine help with COPD?

Yes, evidence shows that N-acetylcysteine can reduce the number of acute exacerbations, which are sudden flare-ups of symptoms. However, this benefit was specifically noted for lower doses (600 mg or less per day). It did not significantly improve lung function or quality of life scores.

Is N-acetylcysteine safe to take?

The study found that N-acetylcysteine was not associated with an increased risk of adverse events compared to the control group. It appeared to be a safe option for reducing flare-ups in patients with COPD, but you should always consult your doctor before starting new supplements.

Does it matter how much N-acetylcysteine I take?

Yes, the amount matters. The data showed a significant reduction in flare-ups for those taking 600 mg or less per day. For those taking higher doses (more than 600 mg per day), there was no statistically significant benefit found in the study.

Study Details

Study typeMeta analysis
Sample sizen = 2,856
EvidenceLevel 1
PublishedJan 2026
View Original Abstract ↓
INTRODUCTION: This study aimed to evaluate the efficacy and safety of N-acetylcysteine (NAC) in patients with chronic obstructive pulmonary disease (COPD). METHODS: This systematic review was registered in PROSPERO (CRD42024597263). In February 2026, a systematic search of PubMed, Embase, Web of Science, and the Cochrane Library was conducted to identify eligible published studies. The methodological quality of the included studies was assessed using the Cochrane Collaboration's risk-of-bias tool. Statistical analyses, including the generation of forest plots, were performed using Review Manager software. RESULTS: Fourteen randomized controlled trials involving 2,856 patients were included in the final analysis. The primary analysis of acute exacerbations included 2,609 participants, with 1,295 patients in the NAC group and 1,314 in the control group. Compared with the control group, NAC was associated with a reduced incidence of acute exacerbations in patients with COPD (risk ratio (RR) = 0.87, 95% confidence interval (CI) [0.79-0.96],  = 0.006). Subgroup analysis by NAC dosage showed that low-dose NAC (≤600 mg/day) was associated with a lower risk of acute exacerbations (RR = 0.84, 95% CI [0.73-0.97],  = 0.02), whereas high-dose NAC (>600 mg/day) showed no statistically significant benefit (RR = 0.88, 95% CI [0.73-1.06],  = 0.19). In addition, NAC did not significantly improve pulmonary function, including forced expiratory volume in one second (FEV1) and forced vital capacity (FVC), St. George's Respiratory Questionnaire scores, or glutathione (GSH) levels. NAC was also not associated with an increased risk of adverse events compared with the control group. CONCLUSIONS: These findings suggest that NAC may reduce the risk of acute exacerbations in patients with COPD without increasing drug-related adverse events. However, the available evidence does not indicate clear benefits for pulmonary ventilation, quality of life, or GSH levels. Further high-quality, large-scale, and rigorously designed randomized controlled trials are needed to confirm these findings.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.